Activity and tolerability of combination of trastuzumab deruxtecan with olaparib in preclinical HER2+and HER2-low breast cancer models

被引：2
|
作者：
Proia, Theresa
Wallez, Yann
Bashi, Azadeh Cheraghchi
Wilson, Zena
Randle, Suzanne
Anderton, Mark
Carroll, Danielle
Rasheed, Zeshaan
Pease, J. Elizabeth
Leo, Elisabetta
Mettetal, Jerome
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-13-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-13-18
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer
    Shimomura, Akihiko
    Takano, Toshimi
    Takahashi, Shunji
    Sagara, Yasuaki
    Watanabe, Junichiro
    Tokunaga, Eriko
    Shinkai, Tetsu
    Kamio, Takahiro
    Kikumori, Kunika
    Kamiyama, Emi
    Fujisaki, Yoshihiko
    Saotome, Dan
    Yamashita, Toshinari
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (01) : 160 - 169
  • [22] DIFFERENTIAL SURVIVAL IMPACT OF TRASTUZUMAB DERUXTECAN IN HER2-POSITIVE VERSUS HER2-LOW BREAST CANCER PATIENTS WITH BRAIN METASTASES
    Ranjan, Tulika
    Podder, Vivek
    Bardhan, Mainak
    Mccracken, Andrea
    Hurmiz, Charlie
    Mahtani, Reshma L.
    Ahluwalia, Manmeet Singh
    NEURO-ONCOLOGY, 2024, 26
  • [23] Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models
    Arshad, Maryam
    Azad, Abul
    Chan, Phoebe Yuen Ka
    Vigneswara, Vasanthy
    Feldinger, Katharina
    Nafi, Siti Norasikin Mohd
    Laporte-Maguire, Eloise
    De Santo, Carmela
    Zuo, Jianmin
    Shaaban, Abeer M.
    Kong, Anthony
    BRITISH JOURNAL OF CANCER, 2024, 130 (12) : 1990 - 2002
  • [24] Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States
    Lang, Yitian
    Wu, Bin
    Liu, Xiaoyan
    BREAST CANCER-TARGETS AND THERAPY, 2022, 14 : 453 - 463
  • [25] Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
    Testa, Stefano
    Dickerson, James C.
    Telli, Melinda
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 11
  • [26] Enhertu (Fam-trastuzumab-deruxtecan-nxki) - Revolutionizing treatment paradigm for HER2-Low breast cancer
    Siddiqui, Tasmiyah
    Rani, Payal
    Ashraf, Tayyaba
    Ellahi, Aayat
    ANNALS OF MEDICINE AND SURGERY, 2022, 82
  • [27] Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases
    Khatri, Vaseem M.
    Mestres-Villanueva, Mariella A.
    Yarlagadda, Sreenija
    Doniparthi, Ajay
    Smith, David B.
    Nakashima, Justyn Y.
    Bryant, John M.
    Zhao, Dekuang
    Upadhyay, Rituraj
    Mills, Matthew N.
    Oliver, Daniel E.
    Yu, Hsiang-Hsuan Michael
    Palmer, Joshua D.
    Williams, Nicole O.
    Mahtani, Reshma L.
    Ahluwalia, Manmeet S.
    Soliman, Hatem H.
    Han, Hyo S.
    Soyano, Aixa E.
    Kim, Youngchul
    Kotecha, Rupesh
    Beyer, Sasha J.
    Ahmed, Kamran A.
    NPJ BREAST CANCER, 2024, 10 (01)
  • [28] Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
    Wolff, Antonio C.
    Mcshane, Lisa M.
    Allison, Kimberly H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (08): : 829 - 831
  • [29] Trastuzumab deruxtecan for HER2+advanced breast cancer
    Lee, Jiyun
    Park, Yeon Hee
    FUTURE ONCOLOGY, 2021, 18 (01) : 7 - 19
  • [30] Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report
    Wolf, Benita
    Dunet, Vincent
    Dubruc, Estelle
    Dolcan, Ana
    Lalonde, Marie Nicod
    Schiappacasse, Luis
    Zaman, Khalil
    CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 1425 - 1435
12345